Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jan 10:14:18.
doi: 10.1186/1471-2334-14-18.

Rifampicin mono-resistant tuberculosis in France: a 2005-2010 retrospective cohort analysis

Vanina Meyssonnier, Thuy Van Bui, Nicolas Veziris, Vincent Jarlier, Jérôme Robert  1
Affiliations

Rifampicin mono-resistant tuberculosis in France: a 2005-2010 retrospective cohort analysis

Vanina Meyssonnier et al. BMC Infect Dis. .

Abstract

Background: Rifampicin resistance is a risk factor for poor outcome in tuberculosis. Therefore, we sought to describe the characteristics and management of Rifampicin monoresistant (RMR) tuberculosis (TB) in France.

Methods: We conducted a retrospective cohort analysis in 2012 on RMR TB patients diagnosed in France between 2005 and 2010 by using a national laboratory network. A standardized questionnaire was used to collect basic demographic data, region of birth, history of TB, HIV-coinfection, alcohol use, and antituberculosis treatment. Outcome was assessed after at least 18 months of follow-up.

Results: A total of 39 patients with RMR TB were reported (0.12% of all TB cases). Overall, 19 (49%) had a previous history of treatment, 9 (23%) were HIV-coinfected, and 24 (62%) were smear-positive. Patient with secondary RMR were more likely to have alcohol abuse (P = 0.04) and HIV-coinfection (p = 0.04). Treatment outcome could be assessed for 30 patients, the nine others being dead or lost to follow-up. A total of 20 (67%) of the 30 assessed were cured, 3 (10%) died, 3 (10%) relapsed, and 4 (13%) were lost to follow up. Four (13%) received less than 6 months of treatment, 3 did not have any modification of the standardized regimen, 13 (43%) received fluoroquinolones, 4 (13%) aminoglycosides, and 8 (26%) a combination of both.

Conclusions: RMR TB is a rare disease in France, and its management was heterogeneous. The lack of treatment standardization may be a consequence of low expertise and may lead to the unsatisfactory low success rate.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patients’ survival (Kaplan-Meier analysis) according to previous history of treatment.
See this image and copyright information in PMC

References

    1. World Health Organization. Global tuberculosis report 2013. http://www.who.int/tb/publications/global_report/en/
    1. American Thoracic Society, Centers for Disease Control and Prevention. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med. 2000;14:1376–1395. - PubMed
    1. Meyssonnier V, Veziris N, Bastian S, Texier-Maugein J, Jarlier V, Robert J. Increase in primary drug resistance of Mycobacterium tuberculosis in younger birth cohorts in France. J Infect. 2012;14:589–595. - PubMed
    1. Ridzon R, Whitney CG, McKenna MT, Taylor JP, Ashkar SH, Nitta AT. et al. Risk factors for rifampin mono-resistant tuberculosis. Am J Respir Crit Care Med. 1998;14:1881–1884. - PubMed
    1. Khuê PM, Truffot-Pernot C, Texier-Maugein J, Jarlier V, Robert J. A 10-year prospective surveillance of Mycobacterium tuberculosis drug resistance in France 1995–2004. Eur Respir J. 2007;14:937–944. - PubMed